All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @theregendoc on TikTok · 58s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @theregendoc's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Tell me what falls down is and why it matters for aging.
  2. 0:02It's the holy grail of anti-aging. It's basically the combination of not just preserving muscle,
  3. 0:08but also reducing systemic inflammation. And so most people understand that peptide is just a
  4. 0:12signal to your body. So what's the signal that follows statin sending? It's going to reduce
  5. 0:16your intrinsic biological age by up to nine years. Why is that? It's because it's going to reduce
  6. 0:21systemic inflammation, which is probably the biggest driver of aging. And then on top of that,
  7. 0:26while a statin has an antagonistic relationship with myostatin. So obviously this isn't going to
  8. 0:30take your myostatin levels to zero. You're not going to be deficient, but it will lower them
  9. 0:34enough that it will allow you to increase lean body mass and make it easier for you to put on muscle.
  10. 0:40And most importantly, I think for the average person, it's going to prevent muscle loss as you
  11. 0:44get older. The biggest issue with intermittent fasting with all these weight loss drugs is
  12. 0:49that you're losing fat and muscle. And people don't realize body recomposition, just fat loss,
  13. 0:54and there's weight loss. Most people are just doing weight loss. They're not doing fat loss.

Follistatin gene therapy and the '9 years younger' claim, fact-checked

doctor.adeel

TikTok creator

30.9K viewsWatch on TikTok

Quick answer

The creator promotes follistatin gene therapy as capable of reducing biological age by 9 years via a single injection, citing myostatin inhibition and anti-inflammatory effects as the primary mechanisms. While the myostatin-follistatin antagonism is supported by animal and limited human disease-population data, no controlled clinical trial in healthy adults has validated the 9-year biological age claim. The therapy remains experimental, is not FDA-approved for anti-aging indications, and carries unresolved safety questions including potential effects on tumor-suppressive pathways.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 5 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Follistatin gene therapy and the '9 years younger' claim, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Follistatin gene therapy and the '9 years younger' claim, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Follistatin gene therapy and the '9 years younger' claim, fact-checked" from doctor.adeel. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator promotes follistatin gene therapy as capable of reducing biological age by 9 years via a single injection, citing myostatin inhibition and anti-inflammatory effects as the primary mechanisms.

The reason this review is not generic is the source wording and the canonical claim label "peptides dr khan in episode 1098 of the human upgrade podcast delves." In this clip, the useful excerpt is: "Tell me what falls down is and why it matters for aging." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Follistatin's ability to inhibit myostatin is real, established biology documented in animal models and a small Becker muscular dystrophy trial (Mendell et al.
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator promotes follistatin gene therapy as capable of reducing biological age by 9 years via a single injection, citing myostatin inhibition and anti-inflammatory effects as the primary mechanisms.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator promotes follistatin gene therapy as capable of reducing biological age by 9 years via a single injection, citing myostatin inhibition and anti-inflammatory effects as the primary mechanisms. While the myostatin-follistatin antagonism is supported by animal and limited human disease-population data, no controlled clinical trial in healthy adults has validated the 9-year biological age claim. The therapy remains experimental, is not FDA-approved for anti-aging indications, and carries unresolved safety questions including potential effects on tumor-suppressive pathways.
  • The '9-year biological age reduction' claim has no published RCT or controlled human trial to support it. It appears to originate from a single self-reported biohacking experiment.
  • Follistatin's ability to inhibit myostatin is real, established biology documented in animal models and a small Becker muscular dystrophy trial (Mendell et al., 2015, Molecular Therapy), not in healthy aging adults.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The '9-year biological age reduction' claim has no published RCT or controlled human trial to support it. It appears to originate from a single self-reported biohacking experiment.
  • Follistatin's ability to inhibit myostatin is real, established biology documented in animal models and a small Becker muscular dystrophy trial (Mendell et al., 2015, Molecular Therapy), not in healthy aging adults.
  • Follistatin gene therapy is not FDA-approved for anti-aging use. Any clinic offering it outside a registered clinical trial is operating outside standard regulatory frameworks.
  • Myostatin also plays roles in tissue regulation beyond muscle. Suppressing it carries theoretical oncological risks that have not been fully characterized in long-term human studies.
  • Inflammaging, the chronic low-grade inflammation associated with aging, is a legitimate research area (Franceschi et al., 2018, Nature Reviews Immunology), but no human trial has shown follistatin therapy specifically reduces it by a clinically meaningful amount.
  • Muscle preservation during GLP-1 therapy is a legitimate clinical concern, but the evidence-based intervention remains resistance training plus adequate dietary protein, not experimental gene therapy.
  • Follistatin is a glycoprotein, not a peptide. Framing it within peptide therapy contexts conflates two distinct categories with different mechanisms, safety profiles, and regulatory statuses.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @theregendoc actually say?

The creator described follistatin as "the holy grail of anti-aging" and claimed it can "reduce your intrinsic biological age by up to nine years" through a single injection. The mechanism offered was twofold: follistatin suppresses myostatin, which preserves or builds muscle, and it reduces "systemic inflammation, which is probably the biggest driver of aging." They also framed it as a solution to the muscle-loss problem associated with GLP-1 drugs and intermittent fasting, arguing most people chase weight loss instead of true body recomposition. These are bold, specific, clinical-sounding claims being made on a platform where the average viewer has no way to evaluate the underlying evidence, and that context matters a lot here.

Does the science back this up?

The myostatin-antagonism part is real biology. The "9-year biological age reduction" claim is not supported by peer-reviewed human trial data. Follistatin is a naturally occurring glycoprotein that does inhibit myostatin, a negative regulator of skeletal muscle growth. Animal studies, particularly in mice and nonhuman primates, have shown meaningful muscle mass increases with follistatin gene delivery (Kota et al., 2009, Science Translational Medicine). A small, much-cited human study by Mendell et al. (2015, Molecular Therapy) tested follistatin gene therapy in Becker muscular dystrophy patients and showed some functional improvement, but this was a disease population, not healthy aging adults. The "nine years" figure appears to originate from a single-patient, self-reported biological age test promoted in biohacking circles, not a controlled clinical trial. No peer-reviewed study in healthy humans has demonstrated a 9-year reduction in biological age from follistatin therapy. The inflammation claim is also plausible in theory but lacks direct clinical evidence in humans at this time.

What did they get wrong (or right)?

Credit where it is due: the creator correctly identified myostatin as a muscle growth inhibitor and follistatin as its antagonist. That relationship is well-established. They are also right that muscle loss during rapid weight loss is a real clinical concern, and that distinction between weight loss and fat loss matters. Those points are accurate and useful. Where they went wrong is presenting a single anecdotal data point, "up to nine years" of biological age reversal, as if it were an established clinical outcome. It is not. They also called follistatin a peptide, which is technically imprecise. Follistatin is a glycoprotein, not a peptide in the conventional sense used in peptide therapy contexts. More importantly, the framing of this as something ready for general use glosses over the fact that follistatin gene therapy is still experimental, not commercially approved, and carries real unknowns around cancer risk, since myostatin also plays a role in regulating tumor suppression in some tissues.

What should you actually know?

Follistatin gene therapy is genuinely interesting science that is nowhere near ready for routine clinical use in healthy people. The leap from "promising animal data plus one muscular dystrophy trial" to "get this injection and lose 9 biological years" is enormous, and viewers deserve to know that gap exists. The biohacking community, including platforms like the Human Upgrade Podcast, has a pattern of treating n-of-1 experiments as proof of concept. That is not how evidence works. If you are interested in preserving muscle mass as you age, resistance training combined with adequate protein intake has far more clinical evidence behind it than any gene therapy currently accessible outside a trial. If you are losing muscle on a GLP-1 drug, that is a real conversation to have with a physician, not a reason to seek experimental gene delivery. Anyone offering follistatin gene therapy outside of a registered clinical trial is operating outside established regulatory frameworks, and that alone should prompt serious skepticism.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

doctor.adeel · TikTok creator

30.9K views on this video

Dr. Khan, in Episode 1098 of the Human Upgrade Podcast, delves into the groundbreaking world of anti-aging with an emphasis on Follistatin Gene Therapy. This revolutionary therapy offers the potential to reduce your biological age by a remarkable 9 years through a single injection. In our discussion, we explore the transformative effects of this therapy, not only in preserving muscle but also in significantly reducing systemic inflammation. During the podcast, we unravel the intricate signals t

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the '9-year biological age reduction' claim has no published rct?

The '9-year biological age reduction' claim has no published RCT or controlled human trial to support it. It appears to originate from a single self-reported biohacking experiment.

What does the video say about follistatin's ability to inhibit myostatin?

Follistatin's ability to inhibit myostatin is real, established biology documented in animal models and a small Becker muscular dystrophy trial (Mendell et al., 2015, Molecular Therapy), not in healthy aging adults.

What does the video say about follistatin gene therapy?

Follistatin gene therapy is not FDA-approved for anti-aging use. Any clinic offering it outside a registered clinical trial is operating outside standard regulatory frameworks.

What does the video say about myostatin also plays roles in tissue regulation beyond muscle. suppressing?

Myostatin also plays roles in tissue regulation beyond muscle. Suppressing it carries theoretical oncological risks that have not been fully characterized in long-term human studies.

What does the video say about inflammaging, the chronic low-grade inflammation associated with aging,?

Inflammaging, the chronic low-grade inflammation associated with aging, is a legitimate research area (Franceschi et al., 2018, Nature Reviews Immunology), but no human trial has shown follistatin therapy specifically reduces it by a clinically meaningful amount.

What does the video say about muscle preservation during glp-1 therapy?

Muscle preservation during GLP-1 therapy is a legitimate clinical concern, but the evidence-based intervention remains resistance training plus adequate dietary protein, not experimental gene therapy.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by doctor.adeel, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.